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A B S T R A C T
Background
Epilepsy is a common neurological condition that affects up to 1% of the population. Nearly 30% of people with epilepsy are resistant to
currently available antiepileptic drugs (AEDs) and require treatment with multiple antiepileptic drugs in combination. Tiagabine is one of
the newer AEDs that can be used as an adjunct (add-on) to standard AEDs.
Objectives
To evaluate the efficacy and tolerability of tiagabine when used as an add-on treatment for people with drug-resistant focal seizures.
Search methods
This is an updated Cochrane review, last published in 2014. For the latest update, we searched the following databases on 22 January 2019:
Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group's Specialized Register and the Cochrane Central
Register of Controlled Trials, MEDLINE (Ovid, 1946 to January 21, 2019), ClinicalTrials.gov, and the WHO International Clinical Trials Registry
Platform. We imposed no language restrictions. We also contacted the manufacturers of tiagabine and experts in the field to identify any
ongoing or unpublished studies.
Selection criteria
We included randomised placebo-controlled add-on trials conducted in people of any age with focal epilepsy. The studies could be dou-
ble-, single-, or unblinded and of parallel or cross-over design. They had to have a minimum treatment period of eight weeks. We also
included trials using an active drug control group.
Data collection and analysis
Two review authors independently assessed trials for inclusion and extracted data according to the standard methodological procedures
expected by the Cochrane Collaboration for this review update. We resolved disagreements by discussion. Outcomes investigated included
50% or greater reduction in seizure frequency, treatment withdrawal, adverse effects, effects on cognition and quality of life. The primary
analyses were performed by intention-to-treat. We calculated worst-case and best-case analyses for seizure outcomes. We evaluated dose
response using regression models. Two review authors assessed risk of bias in each study using the Cochrane 'Risk of bias' tool.
Main results
No further studies were added since the previous update in 2014. The review included six trials (four parallel-group and two cross-over
group trials) consisting of 948 participants. For the main comparison, tiagabine versus placebo, all participants were aged between 12 and
77 years and the study treatment periods ranged from 12 to 22 weeks. The overall risk ratio (RR) with 95% confidence intervals (CIs) for
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a 50% or greater reduction in seizure frequency (tiagabine versus placebo) was 3.16 (95% CI 1.97 to 5.07; 3 trials; 769 participants; high-
certainty evidence). Because of differences in response rates among trials, regression models were unable to provide reliable estimates of
response to individual doses. The RR for treatment withdrawal (tiagabine versus placebo) was 1.81 (95% CI 1.25 to 2.62; 3 trials, 769 partic-
ipants; moderate-certainty evidence). Dizziness and tremor were significantly associated with tiagabine therapy. For cognitive and qual-
ity-of-life outcomes, the limited available data suggested no significant effects on cognition, mood, or adjustment. One trial comparing
tiagabine with an active drug control group (tiagabine versus topiramate) found no significant differences between the two add-on drugs
for a 50% or greater reduction in seizure frequency (RR 0.54, 95% CI 0.19 to 1.58; 1 trial; 41 participants) or for treatment withdrawal (RR
1.43, 95% CI 0.74 to 2.74; one trial; 41 participants). We judged two of the six included studies to have low risk of bias, three studies to have
an unclear risk of bias, and one study to have a high risk of bias. Methods for randomisation sequence generation were the least reported
trial design factor and generated the most concerns regarding risk of bias. We rated the overall certainty of the evidence as largely moder-
ate to high using the GRADE approach. We rated the evidence for two of the adverse effect outcomes, nausea and tremor, as low certainty.
Authors' conclusions
Tiagabine reduced seizure frequency but was associated with some adverse effects when used as an add-on treatment in people with
drug-resistant focal epilepsy. The findings of the current review are mainly applicable to adults and adolescents, and may not necessarily
be applicable to children as none of the trials included participants aged under 12 years. We found no significant differences between
tiagabine and topiramate as add-on drugs; however, evidence was provided by a single trial and was therefore limited.
P L A I N   L A N G U A G E   S U M M A R Y
Tiagabine add-on therapy for drug-resistant focal epilepsy
Background
Epilepsy is a disorder in which recurrent seizures are caused by abnormal electrical discharges from the brain. Most seizures can be con-
trolled by a single antiepileptic drug. Unfortunately, some people require more than one antiepileptic drug to control their seizures (drug-
resistant epilepsy), especially if the seizures originate from one area of the brain (focal epilepsy), rather than affecting the entire brain
(generalised epilepsy).
Tiagabine is a newer antiepileptic drug that can be used in conjunction with a person's normal antiepileptic drug regimen. This review
assessed the evidence available for how effective tiagabine is in reducing seizures, as well as looking at the side effects that may be asso-
ciated with its use when it is used alongside other antiepileptic medication(s) for people with drug-resistant focal epilepsy.
Results
We found six trials that included 948 people with focal epilepsy. These trials were all randomised controlled trials (RCTs) that compared the
antiepileptic drug tiagabine with a placebo (an inactive, dummy treatment which should not affect epilepsy) or with a different antiepilep-
tic drug for a period of up to 24 weeks. We found that tiagabine, when used with another antiepileptic drug, was three times more effective
than placebo at reducing the number of seizures in people with drug-resistant focal epilepsy. Adding tiagabine to people's usual treatment
was, however, associated with an increase in side effects, such as dizziness and tremor. People using tiagabine were over four times more
likely to experience tremor than those using placebo; however, only one trial reported this adverse event so the evidence for this is limited.
People taking tiagabine in addition to other drugs were nearly twice as likely to withdraw from treatment than those taking placebo. We
found no significant differences between tiagabine and topiramate, another antiepileptic drug, as add-on drugs.
Conclusions
Overall, there was high-certainty evidence for the outcome of seizure reduction, which means that we are confident that the effect we
have reported is accurate. The trials included in this review did not examine the long-term effects of tiagabine as an add-on treatment
or the effects of tiagabine in children aged below the age of 12 years. Future research is needed to determine how tiagabine performs in
comparison with other newer antiepileptic drugs.
The evidence is current to January 2019.
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Summary of findings for the main comparison.   Tiagabine compared to placebo control for drug-resistant focal epilepsy
Tiagabine compared to placebo control for drug-resistant focal epilepsy
Patient or population: People with drug-resistant focal epilepsy
Setting: Hospital outpatient setting
Intervention: Tiagabine
Comparison: Placebo control















Study population50% or greater reduction
in seizure frequency (Inten-
tion-to-treat analysis)
Follow-up range: 12 to 22
weeks








Tiagabine increases the number of partic-
ipants achieving a 50% or greater reduc-
tion in seizure frequency
Study populationTreatment withdrawal
Follow-up range: 12 to 22
weeks








Tiagabine likely increases treatment with-
drawal
Study populationDizziness
Follow-up range: 12 to 22
weeks








Tiagabine likely increases the number of
participants who experience dizziness
Study populationFatigue
Follow-up range: 12 to 22
weeks








Tiagabine probably slightly increases the
number of participants who experience
dizziness
Study populationNausea
Follow-up range: 12 to 22
weeks








Tiagabine may slightly increase the num-
ber of participants who experience nau-









































































































































Follow-up range: 12 to 22
weeks








Tiagabine likely slightly increases the
number of participants who experience
somnolence
Study populationTremor
Follow-up range: 12 to 22
weeks







LOW 2 3 4
Tiagabine may cause a large increase the
number of participants who experience
nausea but we are uncertain
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded once for imprecision - number of events was insufficient and did not satisfy the optimal information size.
2 Downgraded twice for imprecision - very limited number of events was insufficient and did not satisfy the optimal information size.
3 Downgraded once for publication bias - data were published by only one study.
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B A C K G R O U N D
Description of the condition
Epilepsy is a common neurological condition, with an estimated in-
cidence of 50 per 100,000 people and a prevalence of five to 10 per
1000 in the developed world (Sander 1996). It has previously been
estimated that between 2% and 3% of the population will be given
a diagnosis of epilepsy at some time in their lives (Hauser 1993). A
more recent systematic review has, however, highlighted that the
lifetime prevalence of epilepsy is lower, with 7.6 people per 1000
estimated to be affected (95% confidence interval (CI) 6.17–9.38)
(Fiest 2017).
Most people who receive a diagnosis of epilepsy will go into remis-
sion; however, up to 30% will continue to have seizures (i.e. be-
come drug-resistant), despite treatment with adequate doses of an
antiepileptic drug (AED) as monotherapy or in combination with
other AEDs (Cockerell 1995). Individuals with drug-resistant epilep-
sy most commonly have focal-onset seizures, which are divided in-
to three types: simple focal, complex focal, and secondary gener-
alised tonic-clonic seizures (Commission 1989). Focal seizures orig-
inate from one area of the brain and are restricted to one hemi-
sphere. During secondary generalised tonic-clonic seizures, howev-
er, the initial focal-onset seizure evolves such that the entire brain
is then affected, incorporating both hemispheres. For the purposes
of this review, people will be considered drug-resistant if they have
failed to respond to a minimum of two AEDs given as monothera-
py or in combination, according to the definition of drug-resistant
epilepsy recommended by the International League Against Epilep-
sy (ILAE 2010).
Description of the intervention
Over the past 10 to 15 years, there has been renewed interest in the
development of new AEDs as standard drugs (e.g. carbamazepine,
phenytoin, valproate) do not leave all people with epilepsy seizure-
free, and are associated with adverse effects. New AEDs are initial-
ly tested in randomised controlled trials (RCTs) as an add-on treat-
ment for people with drug-resistant focal epilepsy. Because they
have demonstrated a therapeutic effect in these trials, new AEDs
tend to be licensed for add-on use before monotherapy trials have
been undertaken in which new AEDs are compared with standard
AEDs.
Tiagabine is a relatively new AED and was only approved by the US
Food and Drug Administration (FDA) for use as an add-on therapy
for adults and children, over the age of 12 years, with focal-onset
seizures in September 1997 (Food and Drug Administration 1997).
Pharmacokinetic studies in healthy volunteers have demonstrated
that tiagabine is associated with good bioavailability after oral con-
sumption (Gustavson 1995). Specifically, tiagabine displays linear
pharmacokinetics with the maximum serum concentration (over
95% of the drug) being achieved within two hours after dosing (Gus-
tavson 1995).
How the intervention might work
Tiagabine is derived from the gamma-aminobutyric acid (GABA)
uptake inhibitor, nipecotic acid. It exerts its antiepileptic effect by
inhibiting presynaptic and glial uptake of GABA, the main inhibito-
ry neurotransmitter of the brain (Ostergaard 1995; Morimoto 1997).
This action increases the availability of extracellular GABA in the
brain, thereby increasing inhibition of neuronal electrical activity.
Tiagabine thus produces an overall reduction in cortical excitabili-
ty (Fink-Jensen 1992).
Why it is important to do this review
This Cochrane Review is part of a series of reviews conducted to in-
vestigate the newer AEDs. Early reviews of tiagabine reported its ef-
fects on seizure frequency and adverse effects (Marson 1996; Mar-
son 1997). These reviews investigated the most common adverse
effects associated with tiagabine; however, they did not assess any
potential cognitive effects that tiagabine might have. Specifical-
ly, there is concern that AEDs may impair cognitive abilities (Eddy
2011). As a consequence, we have included outcomes that assess
cognitive effects and we have also chosen to include quality-of-life
outcomes, so as to assess the global impact of this drug on well-be-
ing. In this review, we assessed the effects of tiagabine on seizures,
adverse effects, cognition, and quality of life, when used as add-on
treatment for people with drug-resistant focal seizures.
O B J E C T I V E S
To evaluate the efficacy and tolerability of tiagabine when used as
an add-on treatment for people with drug-resistant focal seizures.
M E T H O D S
Criteria for considering studies for this review
Types of studies
1. RCTs.
2. Double-blind, single-blind, or unblinded trials.
3. Placebo-controlled or active drug control group.
4. Parallel-group or cross-over studies.
5. Minimum treatment period of eight weeks.
Types of participants
People of any age with drug-resistant localisation-related (fo-
cal-onset) seizures (i.e. experiencing simple focal, complex focal, or
secondary generalised tonic-clonic seizures).
Types of interventions
The active treatment group received treatment with tiagabine,
in addition to conventional AED treatment; the control group re-
ceived matched placebo or a different add-on AED, in addition to
conventional AED treatment.
Types of outcome measures
Primary outcomes
50% or greater reduction in seizure frequency
We chose the proportion of people with a 50% or greater reduction
in seizure frequency during the treatment period compared with
the pre-randomisation baseline period as the primary outcome. We
chose this outcome as it is commonly reported in this type of study,
and can be calculated for studies that do not report it directly, pro-
vided that baseline seizure data have been reported.
Tiagabine add-on therapy for drug-resistant focal epilepsy (Review)
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Secondary outcomes
Treatment withdrawal
We used the proportion of people who had treatment withdrawn
during the course of the treatment period as a measure of global
effectiveness. Treatment is likely to be withdrawn because of ad-
verse effects, lack of efficacy, or a combination of the two, and this
is an outcome to which individuals make a direct contribution. In
trials of short duration, it is likely that adverse effects will be the
most common reason for withdrawal.
Adverse e6ects
1. The proportion of people experiencing any of the following five
adverse effects, considered by the review authors to be common






2. The proportion of people experiencing the five most common ad-
verse effects if different from point 1 above.
Cognitive e6ects
To date, no consensus has been reached on which instruments
should be used to assess the effects of AEDs on cognition. As a re-
sult, the assessment of cognitive effects has been approached in a
heterogeneous way (Cochrane 1998). In view of this difficulty, we
tabulated results, but made no attempt to combine results in a
meta-analysis.
Quality of life
Once again, no consensus has been reached on which instruments
should be used to assess quality of life (Baker 2000); we therefore
tabulated results, but made no attempt to combine results in a
meta-analysis.
Search methods for identification of studies
Electronic searches
This review is an update of a Cochrane Review first published in
1999. We ran searches for the original review in 1999, and ran sub-
sequent searches in June 2003, March 2005, January 2008, June
2010, December 2011, and November 2013. For the latest update,
we searched the following databases on 22 January 2019, with no
language restrictions.
1. The Cochrane Register of Studies (CRS Web; includes the
Cochrane Epilepsy Group's Specialized Register and the
Cochrane Central Register of Controlled Trials CENTRAL), using
the search strategy outlined in Appendix 1.
2. MEDLINE (Ovid, 1946 to January 21, 2019), using the search strat-
egy outlined in Appendix 2.
3. ClinicalTrials.gov, using the search strategy outlined in Appen-
dix 3.
4. WHO International Clinical Trials Registry Platform (ICTRP), us-
ing the search terms: tiagabine AND epilepsy.
For the search conducted 4 August 2016, we searched the following
databases, with no language restrictions.
1. The Cochrane Epilepsy Group Specialized Register (4 August
2016), using the search strategy outlined in Appendix 4.
2. The Cochrane Central Register of Controlled Trials (CENTRAL)
via the Cochrane Register of Studies Online (CRSO; 4 August
2016), using the search strategy outlined in Appendix 5.
3. MEDLINE Ovid (1946 to 4 August 2016), using the search strategy
outlined in Appendix 6.
4. ClinicalTrials.gov (4 August 2016), using the search terms:
Tiagabine AND epilepsy.
5. WHO International Clinical Trials Registry Platform (ICTRP; 4 Au-
gust 2016), using the search terms: Tiagabine AND epilepsy.
Searching other resources
We reviewed the reference lists of retrieved studies to search for ad-
ditional reports of relevant studies.
We contacted Sanofi-Synthelabo (makers of tiagabine) and experts
in the field to ask for information about unpublished or ongoing
studies.
Data collection and analysis
Selection of studies
In the previous versions of the review, two review authors (RB and
KMM) had independently extracted data and assessed risk of bias
for the studies included (Pulman 2012; Pulman 2014). For the cur-
rent review update, two new review authors (RB and KMM) inde-
pendently assessed the eligibility of studies for inclusion from the
most recent searches. We resolved disagreements by mutual dis-
cussion.
Data extraction and management
We extracted the following information for each trial, using a data
extraction form.
Trial design
1. Methods of sequence generation and randomisation conceal-
ment.
2. Method of blinding.
3. Whether any people had been excluded from reported analyses.
4. Duration of baseline period.
5. Duration of treatment period.
6. Dose(s) of tiagabine tested.
Participant demographic information
1. Total number of people allocated to each treatment group.
2. Age and sex of participants.
3. Number with focal and generalised seizures.
4. Seizure frequency during baseline period.
5. Number of background drugs.
We also contacted study sponsors to confirm the following infor-
mation, if it was not available in the published text:
1. Method of randomisation.
2. Total number randomly assigned to each group.
3. Number of people in each group achieving a 50% or greater re-
duction in seizure frequency per treatment group.
Tiagabine add-on therapy for drug-resistant focal epilepsy (Review)
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4. Number of people having treatment withdrawn post-randomi-
sation per treatment group.
5. For those excluded:
a. the reason for exclusion;
b. whether any of those excluded completed the treatment
phase;
c. whether any of those excluded had a 50% or greater reduc-
tion in seizure frequency during the treatment phase.
Outcomes
We recorded the number of people who experienced each outcome
according to randomly assigned group.
Assessment of risk of bias in included studies
Two review authors (RB and KMM) independently assessed the risk
of bias for each trial, using the Cochrane 'Risk of bias' tool, as de-
scribed in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011). We discussed and resolved disagreements.
We rated included studies as adequate, inadequate, or unclear on
six domains applicable to RCTs: randomisation method, allocation
concealment, blinding methods, incomplete outcome data, selec-
tive outcome reporting, and other sources of bias.
Measures of treatment e6ect
We presented the primary outcome of seizure reduction as a risk
ratio (RR). We also presented the secondary outcomes, including
seizure freedom, treatment withdrawal, and adverse effects, as
RRs.
For continuous outcome data (i.e. cognition and quality of life), we
expected that different measures may have been used for these
outcomes. If we had found this to be the case, we intended to use
the standardised mean difference to present these data if this was
deemed appropriate, and if the data were available.
Unit of analysis issues
The inclusion of cross-over studies in meta-analyses introduces
unit of analysis issues. We had intended to include data from the
first treatment period of each study in the meta-analysis, essen-
tially regarding the first treatment period as a parallel study, and
thus, avoiding any issues of carry-over effect. Two cross-over stud-
ies were included in this review; however, both trial publications
contained insufficient information to allow our planned analyses.
Dealing with missing data
We sought missing data from the study authors. We carried out in-
tention-to-treat (ITT), best-case and worst-case analyses on the pri-
mary outcome to account for missing data. We presented all analy-
ses in the main report.
Assessment of heterogeneity
We assessed clinical heterogeneity by comparing the distribution
of important individual participant factors among trials (e.g. age,
seizure type, duration of epilepsy, number of AEDs taken at the
time of randomisation) and trial factors (e.g. randomisation con-
cealment, blinding, losses to follow-up). We examined statistical
heterogeneity with a Chi2 test and the I2 statistic for heterogeneity;
when we found no significant heterogeneity (P > 0.10), we used a
fixed-effect model. Had we found significant heterogeneity, we in-
tended to use a random-effects model analysis, using the inverse
variance method.
Assessment of reporting biases
We requested all protocols from study authors to enable a compar-
ison of outcomes of interest. We investigated outcome reporting
bias with the ORBIT matrix system (Kirkham 2010). We had planned
to create and examine funnel plots; however, we could not under-
take this because of the small number of trials included.
Data synthesis
We used a fixed-effect model meta-analysis to synthesise the data.
Our preferred estimator was the Mantel-Haenszel RR. For the out-
comes of 50% or greater reduction in seizure frequency and treat-
ment withdrawal, we used 95% CIs. For individual adverse effects,
we used 99% CIs to make an allowance for multiple testing.
We had expected to carry out the following analyses.
1. Intervention group versus controls on seizure reduction.
2. Intervention group versus controls on treatment withdrawal.
3. Intervention group versus controls on adverse effects.
4. Intervention group versus controls on cognitive effects.
5. Intervention group versus controls on quality of life.
We had planned to stratify each analysis by type of control group
(i.e. placebo or active control) and by study characteristics to en-
sure the appropriate combination of study data. However, because
of the limited number of studies eligible for inclusion, the analyses
could not be executed as planned. Instead, we conducted two sepa-
rate comparisons, 'tiagabine versus placebo control' and 'tiagabine
versus topiramate', due to the availability of data, and then ad-
dressed each outcome separately for the two comparisons.
Our analyses included all participants in the treatment group to
which they had been allocated. For the efficacy outcome (50% or
greater reduction in seizure frequency), we undertook three analy-
ses, two of which were sensitivity analyses:
1. Primary (ITT) analysis: participants not completing follow-up or
with inadequate seizure data were assumed to be non-respon-
ders. Analysis by ITT was reported by all of the included studies.
a. Worst-case analysis (sensitivity analysis): participants not
completing follow-up or with inadequate seizure data were
assumed to be non-responders in the intervention group,
and responders in the placebo group.
b. Best-case analysis (sensitivity analysis): participants not
completing follow-up or with inadequate seizure data were
assumed to be responders in the intervention group, and
non-responders in the placebo group.
The purpose of the best-case and worst-case analyses is to test the
whether the assumption made during ITT analysis, that all partici-
pants not completing follow-up or with inadequate seizure data are
non-responders, affects the estimated effect size.
Dose regression analysis
We examined the dose-response relationship using logistic regres-
sion in the framework of generalised linear models (McCullagh
1989), and Generalized Linear Interactive Modelling (GLIM) statisti-
cal software (Smith 2015). For this model, we defined a binary vari-
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able with a value of 0 if the response was less than 50%, and a value
of 1 if it was 50% or higher. Models included an indicator variable for
trials. To examine the effect of dose, we considered the following as
possible explanatory variables: dose levels, dose as a continuous
variable, and logarithmic transformation of dose. We also consid-
ered interactions between dose and trials. We calculated odds ra-
tios (ORs) and response rates.
Cognitive and quality of life data
As stated under Secondary outcomes, we tabulated data for these
outcomes, but made no attempt to undertake a meta-analysis. We
found that trials had not used similar outcome measures, so we did
not undertake a meta-analysis, as it was deemed inappropriate to
do so.
Subgroup analysis and investigation of heterogeneity
We did not plan to undertake any subgroup analyses. Instead, we
had intended to investigate heterogeneity using sensitivity analy-
sis, if it had been deemed appropriate.
Sensitivity analysis
We had intended to carry out sensitivity analysis if we detected ir-
regularities between study quality, characteristics of participants,
interventions, and outcomes. Upon examining the data collected,
sensitivity analyses were not deemed necessary.
Summarising and interpreting results
We used the GRADE approach, as outlined in the GRADE Handbook
(Schünemann 2013), to assess the certainty of the evidence and to
interpret findings. We created 'Summary of findings' tables using
GRADEpro GDT software (which imports data from Review Manag-
er 5 software (GRADEpro GDT 2015)) for the outcomes 50% reduc-
tion in seizure frequency and treatment withdrawal, and for the fol-
lowing adverse effects: dizziness, fatigue, nausea, somnolence, and
tremor.
R E S U L T S
Description of studies
Results of the search
The two most recent searches, conducted August 2016 and January
2019, identified 29 records from the databases outlined in Electron-
ic searches. We removed six duplicates, leaving 23 records, which
we screened for inclusion in the review. All 23 records were exclud-
ed at this point because of irrelevance; no new studies were includ-
ed in this review update. We included a total of six studies in this
review, which had been identified during previous searches, three
of which were included in meta-analyses. See Figure 1 for a diagram
of study flow for the two most recent searches.
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Figure 1.   Study flow diagram for searches conducted August 2016 and January 2019
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Included studies
We found six studies that were eligible for inclusion in this re-
view. All trials were initially sponsored by Novo Nordisk as part
of a pre-licensing programme; however, the drug patent is now
owned by Sanofi-Synthelabo. Three of the four parallel-group stud-
ies identified, plus the two cross-over studies, specifically com-
pared tiagabine with placebo for people with drug-resistant focal
seizures (Crawford 2001; Kalviainen 1998; Richens 1995; Sachdeo
1997; Uthman 1998). The remaining parallel-group study (Fritz
2005) compared tiagabine with an alternative AED, topiramate, in
people with drug-resistant focal seizures.
The trials largely shared the same inclusion and exclusion criteria.
People were excluded from these studies if they had a history of
non-epileptic attacks; any active progressive disease of the cen-
tral nervous system (e.g. brain tumour); any significant illness with-
in the previous three months; any medical or neurological disor-
der requiring frequent changes in medication or dosage; abnormal
laboratory findings that were not attributable to their concomitant
AEDs; a history of drug abuse or addiction (including alcohol); or
poor compliance with past medication or medical advice. Women
who were pregnant or at risk of pregnancy and those who were lac-
tating were also excluded. Valproate monotherapy was not allowed
in two studies (Sachdeo 1997; Uthman 1998).
One parallel trial had a 12-week pre-randomisation baseline peri-
od. People who had eight or more focal seizures during this period
were eligible to be randomly assigned (Kalviainen 1998). The treat-
ment period lasted 22 weeks, and 154 individuals were randomly
assigned - 77 to placebo and 77 to tiagabine 30 mg per day. Data on
cognitive and quality-of-life effects on a subset of 43 people were
reported separately (Kalviainen 1996).
Another parallel trial had an eight-week screening period, a titra-
tion phase of three months and a three-month maintenance phase.
Twenty-one participants were randomly assigned to tiagabine (fi-
nal dose at least 20 mg per day) and 20 were randomly assigned
to topiramate treatment (final dose at least 200 mg per day). This
study reported seizure outcome, cognitive outcome, and quali-
ty-of-life effects (Fritz 2005). Notably, the study did not include a
placebo control arm and, consequently, could not contribute da-
ta to the main comparison (tiagabine versus placebo). Instead, the
data from the study was incorporated into a separate comparison,
tiagabine versus topiramate.
Sachdeo 1997, a parallel-group trial, included an eight-week pre-
randomisation baseline period, and people who had eight or more
seizures during this period were eligible to be randomly assigned.
The treatment period lasted 12 weeks, and 318 individuals were
randomly assigned - 107 to placebo and 211 to tiagabine 32 mg per
day. Of those randomly assigned to tiagabine, 106 were allocated
to receive 16 mg twice a day and 105 were allocated to receive 8
mg four times a day. No effects on cognition or quality of life were
reported for this study.
Another parallel trial had a 12-week pre-randomisation baseline
period. People who had eight or more focal seizures during this pe-
riod were eligible to be randomly assigned. The treatment period
lasted 20 weeks, and 297 individuals were randomly assigned - 91 to
placebo, 61 to 16 mg, 88 to 32 mg and 57 to 56 mg tiagabine per day
(Uthman 1998). Data on cognitive and quality-of-life effects were
reported separately, for a subset of 162 individuals (Dodrill 1997).
The cross-over trials were similar in design, and used what has
been called a response-conditional design (Crawford 2001; Richens
1995). People who had six or more seizures in the eight weeks be-
fore the study were entered into a 12-week screening phase. Dur-
ing the screening phase, all participants were given tiagabine, the
dose of which was titrated up with a target dose of 52 mg per
day in Richens 1995, and 64 mg per day in Crawford 2001. Par-
ticipants with a reduction in seizure frequency of 25% or more
during the screening phase were eligible to be randomly assigned
(hence, response was conditional). Eligible individuals were ran-
domly assigned in a two-by-two cross-over trial, to a sequence of
placebo-tiagabine or tiagabine-placebo. Treatment periods last-
ed seven weeks and the cross-over periods three weeks. Richens
1995 screened 94 individuals, 46 of whom were randomly assigned;
Crawford 2001 screened 88 individuals, 44 of whom were randomly
assigned. The reports for these two studies contained insufficient
information to allow our planned analyses using data from the first
treatment period. For the cohort recruited in Richens 1995, the cog-
nitive effects of tiagabine were reported separately, for a subset of
22 individuals (Sveinbjornsdottir 1994).
In total, the studies assessing seizure outcomes and treatment
withdrawal randomly assigned 948 individuals. Studies assessing
adverse effects randomly assigned 859 participants. Data on cogni-
tive effects were available for 251 individuals, and data on quality
of life were available for 229 individuals. Further details are provid-
ed in the Characteristics of included studies,
Excluded studies
Four studies were previously excluded (Arroyo 2005; Bauer 1995;
Gustavson 1997; Uldall 1995). See Characteristics of excluded stud-
ies tables for reasons for exclusion.
Risk of bias in included studies
Overall, two studies were judged to be at low risk of bias (Kalviainen
1998; Sachdeo 1997), three studies at unclear risk of bias (Crawford
2001; Richens 1995; Uthman 1998), and one study at high risk of bias
(Fritz 2005). For the outcome of 50% reduction in seizure frequency,
the three trials that contributed to the meta-analysis were judged
to be at low risk of bias, overall. The reasons for the 'Risk of bias'
judgements for each domain for each study are summarised in the
'Risk of bias' tables within the Characteristics of included studies
tables. See Figure 2 and Figure 3 for a visual representation of the
risk of bias in all included studies.
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
 
Allocation
All included studies randomly assigned participants to treatment
arms. Of the six trials included, only two used computer-generat-
ed sequences to allocate participants (Fritz 2005; Kalviainen 1998).
The other studies did not provide details on how their sequence al-
location was generated. All but Fritz 2005 used sequentially allocat-
ed sealed packages to conceal group allocation. Fritz 2005 used no
methods of concealment. Overall for sequence generation, we rat-
ed risk of bias as unclear for three studies (Crawford 2001; Richens
1995; Uthman 1998), low for two studies (Kalviainen 1998; Sachdeo
1997), and high for one study (Fritz 2005). For allocation conceal-
ment, we rated risk of bias to be low for five studies and high for
one study (Fritz 2005).
Blinding
All studies reported that they were double-blinded, except for Fritz
2005, which was an open-label study, and thus used no blinding
techniques. In the five other included studies (Crawford 2001; Kalvi-
ainen 1998; Richens 1995; Sachdeo 1997; Uthman 1998), identical
packaging and medication were used to maintain blinding. No spe-
cific details regarding who was blinded were provided in the papers
(i.e. participants, study personnel, or outcome assessors). Overall,
for blinding, we rated risk of bias to be low for five studies and high
for one study.
Incomplete outcome data
All studies reported attrition rates and reasons for dropout. An ITT
analysis was used by all studies to deal with missing data. Overall,
for incomplete outcome data, we rated risk of bias to be low for all
six studies.
Selective reporting
Most of the studies detailed outcomes within the methods of the
paper and reported the data; however, no protocols were available
to allow detailed assessment of this. Fritz 2005 selected a subset of
randomly assigned participants, and reported baseline measures
only for this subset. Overall, for selective reporting, we rated risk of
bias to be low for five studies and unclear for one study.
Other potential sources of bias
When assessing the trials for other sources of bias, we were unable
to detect any other potential sources of bias for two of the includ-
ed trials (Kalviainen 1998; Sachdeo 1997). We hence awarded these
two trials a low 'Risk of bias' judgement. We judged that the remain-
ing four trials were at risk of other potential sources of bias.
The two cross-over trials (Crawford 2001; Richens 1995) shared a
response-conditional study design that required participants to at-
tain a 25% or greater reduction in seizure frequency during the
screening phase so as to be eligible for randomisation into the
treatment phase of the studies. As a result, both trials preselect-
ed participants who were expected to have a clinical response to
tiagabine, thus generating bias. Notably, trials which use this spe-
cific type of study design likely overestimate the therapeutic effec-
tiveness of a given treatment and are assumed to generate biased
findings. We thus assessed both trials to be at a high risk of other
potential sources of bias.
We further judged that the trial by Fritz 2005 was at unclear risk of
other potential sources of bias. There was incomplete reporting of
baseline demographic data for participants. Specifically, baseline
data were not provided for participants who discontinued from the
study. It was, therefore, not possible to determine whether there
were any baseline imbalances in the trial.
Similarly, we assessed that the trial by Uthman 1998 was at unclear
risk of other potential sources of bias. This arose from the unequal
randomisation ratio (3:2:3:2 to placebo, 16 mg, 32 mg, and 56 mg
tiagabine, respectively) used in the study design, and the lack of
reasoning provided to justify its use. Generally, unequal randomi-
sation ratios tend to favour allocation to intervention. Such ran-
domisation ratios are associated with a greater placebo effect as
more participants infer that they have been allocated to the active
treatment (Hey 2014). In contrast, in this study, the randomisation
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ratio favoured allocation to placebo and to tiagabine 32 mg/day.
This could, however, have similarly influenced participants' per-
ception of their treatment allocation and could thus have biased
their responsiveness. Due to the unclear impact that this might
have on the trial data, we awarded the trial an unclear risk of bias
judgement for this domain.
E6ects of interventions
See: Summary of findings for the main comparison Tiagabine
compared to placebo control for drug-resistant focal epilepsy
As already outlined in the description of studies, we found four
parallel-group and two cross-over studies. The cross-over studies
used a response-conditional design, in which participants were giv-
en tiagabine during a screening period, and those with a 25% or
greater reduction in seizure frequency were eligible to be randomly
assigned. The people randomly assigned were, therefore, highly se-
lected and were biased towards a response to tiagabine. We chose
to report the effects on seizure frequency from the parallel-group
and cross-over trials separately. In addition, reports of the cross-
over studies did not provide detailed adverse effect data or data
on treatment withdrawal, and the parallel-group studies only con-
tributed results for these outcomes.
Of the parallel-group studies, three were placebo-controlled. Data
extracted from these studies thus contributed to the main meta-
analysis comparison, 'tiagabine versus placebo control'. We as-
sessed the active-controlled parallel study that examined tiagabine
and topiramate (Fritz 2005), separately, in a second meta-analysis
comparison, 'tiagabine versus topiramate'.
Tiagabine versus placebo control
50% or greater reduction in seizure frequency: parallel trials
A Chi2 test for heterogeneity for the response to tiagabine indicat-
ed no significant heterogeneity between trials (ITT analysis: Chi2 =
0.81, degrees of freedom (df) = 2, P = 0.67; worst-case analysis: Chi2
= 2.64, df = 2, P = 0.27; best-case analysis: Chi2 = 0.97, df = 2, P = 0.61).
The overall RR for a response to tiagabine was 3.16 (95% CI 1.97 to
5.07), indicating that participants were significantly more likely to
respond to tiagabine than to placebo. The RRs for worst-case and
best-case analyses were 1.19 (95% CI 0.88 to 1.62) and RR 6.14 (95%
CI 3.92 to 9.63), respectively (Analysis 1.1; Figure 4).
 
Figure 4.   Forest plot of comparison: 1 Tiagabine versus placebo control—50% or greater reduction in seizure
frequency, outcome: 1.1 50% or greater reduction in seizure frequency.
 
Dose regression analysis
Due to differences in response rates in individual trials, it was not
possible to give valid estimates of precise responses to individual
doses. Instead, the model with the best summary of the log odds
compared Kalviainen 1998 and Uthman 1998 with Sachdeo 1997.
After adjustments for trial effects, this model included two con-
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trasting dose groups: one group comparing placebo and tiagabine
16 mg per day, and the other group comparing tiagabine 30 mg, 32
mg, and 56 mg per day. The reduction in deviance due to dose at
these two levels, with adjustment for trial effects, was 40.6 on 1 df
(P = 0.001). Upon contrast of trials included, the residual deviance
was 4.8 on 5 df.
The estimated OR relative to placebo was 3.67 (95% CI 2.30 to 5.86).
The OR for Uthman 1998 and Kalviainen 1998 versus Sachdeo 1997
was 1.65 (95% CI 1.11 to 2.44).
Actual and estimated response rates are given in Table 1. Although
we were unable to give precise overall estimates for the proportion
of participants responding to individual doses, evidence suggests
an effect for daily doses of tiagabine 30 mg to 56 mg or more. As an
indication of the possible effects we can say that with placebo rates
in the range of 6% to 10%, at least an additional 13%, and possibly
20%, of people similar to those in these trials, would experience a
50% or greater reduction in seizure frequency when taking a dose
of tiagabine 30 mg or more per day.
50% or greater reduction in seizure frequency: cross-over trials
Reports of the cross-over trials contained insufficient data from the
first treatment period to allow the analyses that were planned. We
therefore summarised the reported results from the two cross-over
trials below.
Of the 46 people randomly assigned in Richens 1995, 11 (24%) had
a 50% or greater reduction in seizure frequency of complex focal
seizures in the tiagabine phase versus the placebo phase. Of the 44
people randomly assigned in Crawford 2001, 12 (27%) had a 50%
reduction in seizure frequency in the tiagabine versus the placebo
phase. The proportion of responders was higher than that seen in
the parallel-group trials; this is not surprising, given that people in
the cross-over trials had to have an apparent response to tiagabine
before they were randomly assigned.
Treatment withdrawal: parallel trials
Treatment withdrawal data were available only for the paral-
lel-group trials. A Chi2 test for heterogeneity suggested no signifi-
cant statistical heterogeneity (Chi2 = 1.75, df = 2, P = 0.42). The over-
all RR for discontinuation for any reason was 1.81 (95% CI 1.25 to
2.62), indicating that people were significantly more likely to with-
draw from tiagabine than from placebo (Analysis 1.2).
Adverse e$ects: parallel-group trials
For the parallel-group trials, in addition to the five adverse effects
specified in the protocol for this review, headache, infection, ner-
vousness, and tremor were among the five most commonly report-
ed adverse effects. A Chi2 test for heterogeneity of adverse effects
indicated no significant heterogeneity between trials. The follow-
ing adverse effects were significantly associated with tiagabine:
dizziness (RR 1.69, 99% CI 1.13 to 2.51) and tremor (4.56, 99% CI 1.00
to 20.94). In contrast, the following were not significantly associat-
ed with tiagabine: fatigue (RR 1.38, 99% CI 0.89 to 2.14), nervous-
ness (10.65, 99% CI 0.78 to 146.08), ataxia (1.24, 99% CI 0.34 to 4.55),
nausea (1.24, 99% CI 0.69 to 2.22), somnolence (1.18, 99% CI 0.76 to
1.83), headache (1.15, 99% CI 0.48 to 2.79), and infection (1.00, 99%
CI 0.36 to 2.76) (Analysis 1.3).
Adverse e$ects: cross-over trials
For the cross-over trials, Crawford 2001 reported that eight peo-
ple experienced adverse effects while taking tiagabine and 10 peo-
ple reported adverse effects while taking placebo. While taking
tiagabine, two people reported dizziness and another two reported
a lack of coordination. While taking placebo, three people reported
accidental injury. All other adverse effects were reported by one in-
dividual only. Richens 1995 did not report a detailed breakdown of
adverse effects occurring with tiagabine or placebo.
Cognitive e$ects: parallel-group and cross-over trials
Reviewing the cognitive effects of tiagabine is complicated by the
lack of a uniform of approach to the assessment of such effects (Do-
drill 1997; Kalviainen 1996; Sveinbjornsdottir 1994). In total, the in-
cluded studies used a total of 24 neuropsychological tests, only two
of which - the Stroop test and the Rey auditory verbal learning test -
were used in all three studies that reported cognitive effects. Three
tests were used by two of the three studies, and the remaining 19
tests were used in just one study. Even when the same test had been
used in two or more studies, it was not always clear that the same
aspects of the test had been used. The tests used in the individual
studies are outlined in Table 2.
No statistically significant differences were noted at the 0.01 level
of confidence for any test, and statistically significant differences
at the 0.05 level were seen for only one test (Benton visual reten-
tion test, form F) (Table 3). It is worth noting that the results from
another two tests were close to reaching statistical significance but
did not (P = 0.051). Consequently, the evidence was insufficient to
conclude that tiagabine as an add-on treatment had an effect on
cognition compared with placebo.
Quality-of-life measures
Two reports addressed quality-of-life outcomes (Dodrill 1997;
Kalviainen 1996). Both reported effects on mood and adjustment,
but used different tests to assess them (Table 4). Neither study
found a significant difference between tiagabine and placebo;
hence, evidence was insufficient to conclude that tiagabine had an
effect on quality of life compared with placebo.
Tiagabine versus topiramate
Only Fritz 2005 compared tiagabine with an active control drug
(topiramate); therefore, we did not pool the data for this compari-
son.
50% or greater reduction in seizure frequency
Within Fritz 2005, we did not note any significant differences be-
tween the two add-on drugs (RR 0.54, 95% CI 0.19 to 1.58; Analy-
sis 2.1). According to the study authors' analysis of 37 participants,
three participants (one tiagabine, two topiramate) became seizure-
free; 11 participants (four tiagabine, seven topiramate) reduced
their seizure frequency by 50% or more.
Treatment withdrawal
We found no significant differences between tiagabine and topira-
mate for withdrawal from the study (RR 1.43, 95% CI 0.74 to 2.74;
Analysis 2.2) (Fritz 2005).
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Cognitive e$ects
For this outcome, the authors of Fritz 2005 did not compare the
two add-on AEDs. Both add-on drugs were examined over sepa-
rate time points: baseline to post-titration phase and post-titra-
tion to maintenance phase. Within the first evaluation, baseline to
post-titration, significant deterioration was found within the top-
iramate group in phonemic verbal fluency (P = 0.001), semantic
verbal fluency (P = 0.006), language comprehension (P = 0.002),
working memory (P < 0.05), and visual block tapping (P = 0.032).
A significant deterioration in verbal memory was also found in the
tiagabine group (P = 0.039).
Within the post-titration to maintenance phase, one significant im-
provement was found in mental flexibility in the topiramate group
(P = 0.045). No changes were found in the tiagabine group for any
of the cognitive outcomes.
Quality-of-life measures
Again, Fritz 2005 did not use appropriate analysis; hence, we were
unable to compare the two add-on AEDs. Within the baseline to
post-titration phase, significantly more complaints about medica-
tion were reported within the tiagabine group (P = 0.048). Partic-
ipants taking topiramate reported significantly higher depression
scores (P = 0.011), lower cognitive functioning (P = 0.024), and in-
creased medication adverse effects (P = 0.008).
For the post-titration to maintenance phase evaluation, the
tiagabine group was significantly more fatigued and had less ener-
gy (P = 0.025). No other differences were found from post-titration
to maintenance.
D I S C U S S I O N
Summary of main results
This review assessed the efficacy and tolerability of tiagabine as an
add-on treatment for people with drug-resistant focal epilepsy. Six
trials were included in this review and all trials were initially spon-
sored by Novo Nordisk, as part of a pre-licensing programme. The
drug patent is now owned by Sanofi-Synthelaboe.
Five of the six included trials used adequate methods of allocation
concealment. However, we rated risk of bias for the method of ran-
domisation sequence generation to be low in only two of the tri-
als. All trials, except one (Fritz 2005), were double-blinded and used
identical packaging and medication to maintain this. We rated risk
of bias for missing data as low in all studies. Investigators fully re-
ported attrition and utilised ITT analyses. We had no access to the
protocols for any of the studies; however, we did not consider se-
lective outcome reporting bias to be an issue for the included stud-
ies.
Despite these limitations, this review provided high-certainty ev-
idence that tiagabine reduced seizure frequency for people with
drug-resistant focal seizures compared with placebo. Specifical-
ly, a significantly larger proportion of people who were allocated
to tiagabine achieved a clinically relevant reduction in seizure fre-
quency (50% or greater) and were considered to be responders to
treatment, compared with those who were allocated to placebo. As
a result of the differences in response rates amongst the trials, the
regression model was unable to provide valid estimates for the pro-
portion of participants who would be expected to respond to spe-
cific doses of tiagabine. We can, however, suggest that for people
who are similar to those recruited into the trials reviewed, we might
expect that at least an additional 13%, possibly 20%, of people will
experience a 50% or greater reduction in seizure frequency when
taking a dose of tiagabine 30 mg or more per day, compared with
placebo.
Results for the outcome of treatment withdrawal showed that
tiagabine was more likely to be withdrawn than placebo. In trials of
relatively short duration, such as those reviewed here, this is like-
ly to represent problems with tolerability rather than poor seizure
control. Of the adverse effects investigated, dizziness and tremor
were significantly more likely to occur with tiagabine than with
placebo. It is, however, important to recognise that the evidence
for tremor is very limited, with the outcome being reported only by
a single study. With regards to cognitive and quality-of-life effects,
due to a lack of uniformity in the approach used to test for cognitive
effects and quality of life, as well as the relatively small numbers of
participants tested, evidence was insufficient to conclude whether
tiagabine had an effect on these outcomes.
Given that only one trial included in this review compared add-on
tiagabine with another add-on AED, the results from this study must
be interpreted with caution. Authors of this study compared the
two drugs for only two of the outcomes included in this review. Giv-
en the increasing number of licensed AEDs, this is an important is-
sue that must be addressed in trials that compare one drug to an-
other.
We should emphasise that the results of this review do not provide
information about the effects of tiagabine when used as monother-
apy, and that the results apply only to focal seizures.
Overall completeness and applicability of evidence
All of the included studies were conducted in adult populations.
Notably, one study (Sachdeo 1997) also included adolescents aged
over 12 years, but none of the studies included children under 12
years old. Consequently, this review is unable to predict the effec-
tiveness or tolerability of tiagabine in children. Furthermore, as dis-
cussed above, only one study (Fritz 2005) investigated the use of
add-on tiagabine compared with that of an alternative AED, topi-
ramate. As a result, this review cannot be considered informative
about the effectiveness or tolerability of tiagabine compared with
other AEDs.
With regards to applicability of the evidence, two of the trials (Craw-
ford 2001; Richens 1995) were associated with limitations that
could impact the applicability of the review findings (and were,
hence, excluded from the meta-analyses). Both trials included the
use of a response-conditional design, the aim of which was to select
and randomly assign a group of people likely to respond favourably
to tiagabine. In theory, this would maximise the effects observed,
and should lead to fewer individuals needing to be recruited into
trials before a significant treatment effect is observed. This is not a
process that mimics clinical practice and the results of these stud-
ies are difficult to translate into everyday clinical practice.
The length of the treatment period was another limitation for all
included trials: seven weeks in the cross-over studies and 12 to 22
weeks in the parallel studies. Clinical practice would be better in-
formed by trials of longer duration, especially for a chronic condi-
tion such as epilepsy.
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Certainty of the evidence
Evidence for the main comparison, 'tiagabine versus placebo con-
trol', was GRADE assessed and a 'Summary of findings' table was
constructed (See Summary of findings for the main comparison).
For all three studies that contributed data to the 'tiagabine versus
placebo control' comparison, we rated the overall risk of bias as
low and considered the evidence to be methodologically sound.
As a result, we did not downgrade the evidence for risk of bias for
any of the outcomes. We did, however, downgrade the evidence for
five of the outcomes (50% or greater seizure reduction, treatment
withdrawal, dizziness, fatigue and somnolence) once to moderate
certainty due to imprecision. Specifically, the number of events
extracted for each of the outcomes was insufficient and did not
satisfy the optimal information size. We then upgraded the evi-
dence for the outcome 50% or greater reduction in seizure frequen-
cy due to the large effect size detected, providing an overall rat-
ing of high-certainty evidence for this outcome. The evidence for
the outcomes treatment withdrawal, dizziness, fatigue and somno-
lence remained rated as moderate certainty.
For the outcomes nausea and tremor we downgraded the evidence
twice for imprecision, as the number of events was exceptionally
low (< 100 events). We rated the evidence as low certainty for the
outcome nausea.We downgraded the evidence for tremor further,
due to suspected publication bias. Data for the outcome tremor
were provided only by one study (Uthman 1998). The other two
studies (Kalviainen 1998; Sachdeo 1997) did not report tremor.
Kalviainen 1998 specified in their publication that an adverse ef-
fect was reported in the journal article only if it had been reported
by more than 5% of participants. Moreover, Sachdeo 1997 stated
that adverse effects were reported only if significantly more partic-
ipants in one, or both, of the two tiagabine treatment groups expe-
rienced an adverse event compared with those receiving placebo.
This therefore implies that data on tremor were not included in the
publications because the adverse event was not commonly report-
ed by study participant, thus contradicting the data extracted from
Uthman 1998. This subsequently led to the suspicion of publication
bias. We then, however, upgraded the evidence for tremor back to
low certainty of evidence due to the large effect size recognised by
Uthman 1998.
Potential biases in the review process
We are not aware of any biases in the review process. We success-
fully conducted an extensive search of the available literature. We
consulted the reference lists of retrieved studies to ensure that
there were no additional references that had not been identified by
the search strategies. We made all attempts to obtain any addition-
al information from the manufacturer of tiagabine, Sanofi-Synthe-
labo, and we contacted experts in the field to enquire about unpub-
lished or ongoing studies. We therefore feel that we exhausted all
possible sources of data relevant to the review.
Agreements and disagreements with other studies or
reviews
Our findings and conclusions for the current review update are con-
sistent with those of previous versions of this review (Pereira 2002;
Pulman 2012; Pulman 2014). This is largely because no further stud-
ies have been identified for inclusion since the addition of Fritz 2005
in the review update completed in September 2010 (Pereira 2002).
We were able to identify another systematic review that similarly
investigated the efficacy of add-on tiagabine (Adkins 1998). In this
review, the authors identified five studies for inclusion. Notably,
all five studies were included in this current review, namely: Craw-
ford 2001; Kalviainen 1998; Richens 1995; Sachdeo 1997; Uthman
1998. Data from all five studies, including the two cross-over studies
(Crawford 2001; Richens 1995), were combined into a single meta-
analysis. Notably, in our review, we only included data from the
two cross-over studies (Crawford 2001; Richens 1995) in a narrative
synthesis and did not combine the data, from these studies, into
the meta-analysis conducted. Despite the fact that the meta-analy-
sis conducted by Adkins 1998 included additional data, not com-
bined into our meta-analysis, the findings of the review remained
in agreement with our current findings, regarding 50% or greater
seizure reduction. The pooled analysis, by Adkins 1998, indicated
that 23% of participants randomised to receive tiagabine attained
a 50% or greater reduction in seizure frequency, opposed to only
9% of the participants who were randomised to placebo. Here, we
calculated a RR of 3.16 (95% CI 1.97 to 5.07). This RR predicts that
participants randomised to tiagabine are three times more likely to
achieve a 50% or greater reduction in seizure frequency than those
randomised to placebo. This is consistent with the statistics report-
ed in the Adkins 1998 review.
A separate review by Leppik 1995 investigated the tolerability of
add-on tiagabine in people with drug-resistant focal epilepsy by
reviewing data from five short-term RCTs and six open-label long-
term extension studies. The review described dizziness, fatigue,
nervousness, tremor, diarrhoea, and depressed mood as the most
commonly reported adverse effects during short-term RCTs. Sim-
ilarly, in this current Cochrane Review update, we observed that
dizziness, tremor, and nervousness were reported by significant-
ly more participants randomised to tiagabine than by those ran-
domised to placebo. The number of participants reporting fatigue,
however, did not reach significance (P = 0.06). We did not address
diarrhoea and depressed mood in this review update; however, it
would advisable to incorporate these adverse effects into future re-
view updates.
The review by Leppik 1995 emphasised that a large majority of
the adverse effects associated with tiagabine were mild to mod-
erate in severity and that they mostly occurred during dose titra-
tion. Importantly, the long-term tolerability profile of tiagabine re-
mained comparable to that observed during short-term use, with
dizziness continuing to be the most commonly reported adverse
event. Likewise tremor, fatigue, and nervousness all continued to
feature among the most frequently reported adverse effects asso-
ciated with tiagabine, but remained mild to moderate in severity.
Accidental injury and infection were also significantly more likely
with tiagabine than with placebo during long-term use. Notably,
the majority of adverse effects were associated with the titration
period, even during longer periods of use, and most resolved within
a month of commencing treatment.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Add-on tiagabine reduced the frequency of seizures for people with
drug-resistant focal seizures. Doses of between 30 mg and 56 mg
per day were likely to reduce the frequency of seizures by 50% or
more, for between 13% and 20% of people. Doses higher than 56
mg per day were not tested in the trials included in this review. De-
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cision-makers should, however, be made aware that withdrawal of
treatment is predicted to occur in twice as many people with add-
on tiagabine than with add-on placebo, and this likely represents
issues with tolerability. Specifically, the evidence presented here
suggests that the adverse effects dizziness and tremor are signifi-
cantly associated with add-on tiagabine.
We found no significant differences in seizure frequency and treat-
ment withdrawal between tiagabine and topiramate as add-on
drugs.
Implications for research
To further evaluate the place of tiagabine in the armamentarium
of available antiepileptic drugs, further studies are required to ad-
dress the following:
• The long-term effects of add-on tiagabine.
• How tiagabine compares with other add-on treatments in drug-
resistant focal epilepsy.
• The role of tiagabine in childhood and generalised epilepsies.
• Economic aspects of tiagabine therapy.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Randomised, double-blind, placebo-controlled, cross-over study, based on a response-dependent de-
sign. Two treatment arms: one TGB, one PCB. Participants randomly assigned to one of two sequences.
TGB started during screening phase at 12 mg/d QID. Seven-week double-blind treatment period during
which participants continued on TGB or crossed over to PCB arm
Participants Multi-centre study (five centres: two in UK, two in The Netherlands, and one in Denmark)
44 participants with drug-resistant focal epilepsy were randomly assigned (30 male), aged 18 to 53
years
Participants already taking one to three background AEDs
Median baseline seizure frequency = 2.7 per week
Interventions Group one: PCB
Group two: TGB (optimal dose 64 mg/d)
Mean daily dose for all randomly assigned participants was 46 mg during the double-blind phase
Outcomes 1. 50% responder rates
2. Median percentage reduction in four-week seizure rate
3. Adverse effects
Notes From the 44 people randomly assigned to the double-blind phase, seven were excluded from the inten-
tion-to-treat analysis. All participants were evaluated for adverse effects. Trial originally sponsored by
Novo Nordisk, now owned by Sanofi-Synthelabo
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "patients were randomly assigned in a 1:1 ratio at each centre to one of
two sequences of treatment"
Comment: No further details on how the sequences were generated
Allocation concealment
(selection bias)
Low risk Comment: Sequentially allocated sealed packages used
Crawford 2001 
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Blinding (performance
bias and detection bias) 
All outcomes




Low risk Comment: Attrition rates reported and intention-to-treat analysis employed
Selective reporting (re-
porting bias)
Low risk Comment: Although no protocol was available, all outcomes reported in meth-
ods section were fully reported in text
Other bias High risk Quote: "The design has ethical advantages because eligibility for randomiza-
tion into the double-blind phase is dependent on patients showing some ther-
apeutic benefit from the study drug (a ≥25% reduction in seizure rate) during
the screening phase. This preselection maximizes the chances of detecting a
difference in clinical response between the study drug and placebo with a rela-
tively low number of patients"
Comment: Study design was biased to detect a therapeutic effect with
tiagabine. The study design also produced a misleading high discontinuation
rate as participants were withdrawn during the screening phase as a result of




Methods Open-label, head-to-head controlled, parallel study. Two treatment arms: one TGB, one TPM. Partic-
ipants were randomly assigned using a non-random component. Duration of screening period: eight
weeks, followed by a titration phase of three months and a maintenance period of three months
Participants No information regarding study sites or countries
41 participants with drug-resistant focal epilepsy randomly assigned, aged 18 to 65 years Baseline data
reported for only 30 participants who completed the whole study (18 male)
Participants already taking one to three background AEDs
Interventions Group one: TGB at least 20 mg/d; mean 32 mg/d
Group two: TPM at least 200 mg/d; mean 335 mg/d
Outcomes 1. 50% responder rates
2. Cognitive effects
3. Quality of life
Notes Non-accurate baseline data reported. Four participants excluded from ITT analysis for seizure reduc-
tion outcome. Trial originally sponsored by Novo Nordisk, now owned by Sanofi-Synthelabo
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Comment: Non-randomisation component employed in the sequence gen-
eration process. Sequence generated by odd versus even number of week in
which participant was seen
Fritz 2005 
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Allocation concealment
(selection bias)
High risk Comment: No concealment used
Blinding (performance
bias and detection bias) 
All outcomes




Low risk Comment: Attrition rates reported and intention-to-treat analysis employed
Selective reporting (re-
porting bias)
Unclear risk Comment: Although no protocol was available, all outcomes reported in meth-
ods section were fully reported in text. Participant characteristics reported for
only 30 participants who completed the whole study of the 41 randomly as-
signed
Other bias Unclear risk Comment: Due to the incomplete reporting of participant characteristics at





Methods Randomised, double-blind, placebo-controlled, two-treatment parallel-group study. Two treatment
arms: one PCB, one TGB. Participants randomly assigned using computer-generated sequence. Treat-
ment period: 22 weeks (six-week run-in period, 12-week fixed-dose period, four-week termination peri-
od)
Participants Multi-centre study (11 centres in Europe—one each in Denmark and Sweden, two in Finland and seven
in UK
154 participants with drug-resistant focal epilepsy were randomly assigned (90 male), aged 17 to 71
years
77 were randomly assigned to placebo and 77 to 30 mg/d tiagabine
Participants already taking one to three background AEDs
Median four-week baseline seizure frequency: placebo = 10.5, tiagabine = 12.2
Cognitive and quality of life effects were assessed on a subset of 43 individuals
Interventions Group one: PCB
Group two: TGB 30 mg/d




5. Quality of life
Notes No participants were excluded from analysis. 29 people withdrew from the study: 21 receiving
tiagabine and eight receiving placebo. Trial originally sponsored by Novo Nordisk, now owned by
Sanofi-Synthelabo
Risk of bias
Bias Authors' judgement Support for judgement
Kalviainen 1998 
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Random sequence genera-
tion (selection bias)
Low risk Quote: "Eligible patients entering the double-blind phase were randomly allo-
cated, according to a computer-generated list"
Allocation concealment
(selection bias)
Low risk Comment: Used sequentially allocated sealed packages
Blinding (performance
bias and detection bias) 
All outcomes




Low risk Comment: Attriition rates reported and ITT analysis employed
Selective reporting (re-
porting bias)
Low risk Comment: Although no protocol was available, all outcomes reported in meth-
ods section were fully reported in text




Methods Randomised, double-blind, placebo-controlled, cross-over study based on a response-dependent de-
sign. Two treatment arms: one PCB, one TGB. Participants randomly assigned using 1:1 ratio. Treat-
ment period: 23 weeks (three-week run-in period, seven-week assessment period, three-week cross-
over period, seven-week assessment period, three-week termination period)
Participants Multi-centre study (five centres in UK and Denmark)
94 participants with drug-resistant focal epilepsy were randomly assigned (61% male), aged 19 to 71
years
25 participants were randomly assigned to placebo-tiagabine sequence and 21 to tiagabine-placebo
Participants already taking one to three AEDs
Median complex focal seizure rate per four weeks = six
Cognitive effects were reported for a subset of 22 individuals
Interventions Group one: PCB
Group two: TGB 52 mg/d QID
Mean daily dose was 33.4 mg (range 12 to 52 mg)
Outcomes 1. 50% responder rates
2. Median percentage reduction in four-week seizure rate
3. Adverse effects
4. Cognitive effects
Notes From the 46 people randomly assigned to the double-blind phase, seven failed to complete the study.
Of these, only four were excluded from the intent-to-treat analysis. All participants were evaluated
for adverse effects. The characteristics of people ineligible for the double-blind phase were similar to
those of people qualifying, with regard to epilepsy history, seizure frequency, and concurrent treat-
ment. Trial originally sponsored by Novo Nordisk, now owned by Sanofi-Synthelabo
Risk of bias
Bias Authors' judgement Support for judgement
Richens 1995 
Tiagabine add-on therapy for drug-resistant focal epilepsy (Review)









Cochrane Database of Systematic Reviews
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Qualifying patients were randomly assigned in a 1:1 ratio at each cen-
tre to one of two treatment sequences"
Comment: No further details of sequence generation
Allocation concealment
(selection bias)
Low risk Comment: Used sequentially allocated sealed packages
Blinding (performance
bias and detection bias) 
All outcomes




Low risk Comment: Attrition rates reported and ITT analysis employed
Selective reporting (re-
porting bias)
Low risk Comment: Although no protocol was available, all outcomes reported in meth-
ods section were fully reported in text
Other bias High risk Quote: "Of the 74 patients who completed the screening phase, 28 were inel-
igible for the double-blind phase because their total seizure rate was not re-
duced by 25% and therefore tiagabine was tapered oC over a 3-week period"
Comment: Study design was biased to detect a therapeutic effect with
tiagabine. The study design also produced a misleading high discontinuation
rate as participants were withdrawn during the screening phase as a result of




Methods Randomised, double-blind, placebo-controlled, parallel-group study. Three treatment arms: one PLC,
two TGB. Participants randomly assigned using ratio 1:1:1 in blocks of six
Treatment periods = 12 weeks
Participants Multi-centre US study (26 centres)
318 participants (178 male) aged 12 to 71 years with drug-resistant focal epilepsy were randomly as-
signed
107 to PBO, 106 to TGB 16 mg BID, 105 to TGB 8 mg QID
Valproate allowed in combination with an enzyme-inducing drug but not as monotherapy
Median baseline four-week complex focal seizures; frequency during baseline was as follows: PCB = 8.4;
TGB 16 mg BID = 8.4; TGB 8 mg QID = 7.9
Interventions Add-on placebo, TGB 16 mg BID or TGB 8 mg QID
Outcomes 1. 50% responder rates
2. Treatment withdrawal
3. Adverse effects
Notes From the 318 people randomly assigned to the double-blind phase, four were excluded from the ITT
analyses. All 318 people were evaluated for adverse effects.
47 people withdrew from the study: 10 receiving PLC; 16 receiving TGB 16 mg BID; 21 receiving TGB 8
mg QID. Trial originally sponsored by Novo Nordisk, now owned by Sanofi-Synthelabo
Risk of bias
Bias Authors' judgement Support for judgement
Sachdeo 1997 
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Random sequence genera-
tion (selection bias)




Low risk Comment: Used sequentially allocated sealed packages
Blinding (performance
bias and detection bias) 
All outcomes





Low risk Comment: Attrition rates reported and ITT analysis employed
Selective reporting (re-
porting bias)
Low risk Comment: Although no protocol was available, all outcomes reported in meth-
ods section were fully reported in text




Methods Randomised, double-blind, placebo-controlled, parallel-group study. Four treatment arms: one PCB,
three TGB. Participants randomly assigned using ratio of 3:2:3:2. Treatment period: 20 weeks (four-
week titration phase, 12-week fixed-dose treatment period, four-week tapering period)
Participants Multi-centre US study (21 centres)
297 participants with drug-resistant focal epilepsy were randomly assigned (172 male), aged 12 to 77
years
Participants already taking one to three AEDs, valproate allowed in combination with an enzyme-in-
ducing drug but not as monotherapy
Median four-week baseline complex focal seizure frequency was: PCB = 7.4; TGB 16 mg = 8.5; TGB 32 mg
= 9.6; TGB 56 mg = 9.1
Cognitive effects were reported for a subset of 162 individuals
Interventions Group one: PCB
Group two: TGB 16 mg/d QID
Group three: TGB 32 mg/d QID
Group 4: TGB 56 mg/d QID




5. Quality of life
Notes From the 297 people randomly assigned to the double-blind phase, five were excluded from the ITT
analyses because no double-blind assessments were done or their centres lacked participants in all
treatment groups. All 297 people were evaluated for adverse effects
54 people withdrew from the study: 13 receiving PCB; six receiving 16 mg TGB; 18 receiving 32 mg TGB,
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "The randomization ratio to treatment groups was 3:2:3:2 for placebo
and 16 mg, 32 mg, and 56 mg or tiagabine (Gabitril), respectively"
Comment: No further details of sequence generation reported in text
Allocation concealment
(selection bias)
Low risk Comment: Used sequentially allocated sealed packages
Blinding (performance
bias and detection bias) 
All outcomes




Low risk Comment: Attrition rates reported and ITT analysis employed
Selective reporting (re-
porting bias)
Low risk Comment: Although no protocol was available, all outcomes reported in meth-
ods section were fully reported in text




• AED = antiepileptic drug;
• BID = twice daily;
• ITT = intention-to-treat;
• PCB = placebo;
• QID = four times daily;
• TGB = tiagabine;
• TPM = topiramate.
.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Arroyo 2005 This is a non-placebo controlled study
Bauer 1995 This is an open add-on study of tiagabine for the treatment of people with resistant focal, secon-
darily generalised seizures, or both. In this study, the results reported were part of an ongoing mul-
ti-national, multi-centre trial. It is not randomised
Gustavson 1997 This is an open-label, single-dose study that was designed to examine the pharmacokinetics of
tiagabine in children with epilepsy. It is not randomised
Uldall 1995 This is a single-blind study of safety, tolerability, and preliminary efficacy of tiagabine as adjunctive
treatment of children with epilepsy. It is not randomised
 
 
D A T A   A N D   A N A L Y S E S
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Comparison 1.   Tiagabine versus placebo control





Statistical method Effect size
1 50% or greater reduction in
seizure frequency
3   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Intention-to-treat analysis 3 769 Risk Ratio (M-H, Fixed, 95% CI) 3.16 [1.97, 5.07]
1.2 Worst-case analysis 3 769 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.88, 1.62]
1.3 Best-case analysis 3 769 Risk Ratio (M-H, Fixed, 95% CI) 6.14 [3.92, 9.63]
2 Treatment withdrawal 3 769 Risk Ratio (M-H, Fixed, 95% CI) 1.81 [1.25, 2.62]
3 Adverse effects 3   Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
3.1 Dizziness 3 769 Risk Ratio (M-H, Fixed, 99% CI) 1.69 [1.13, 2.51]
3.2 Tremor 1 297 Risk Ratio (M-H, Fixed, 99% CI) 4.56 [1.00, 20.94]
3.3 Fatigue 3 769 Risk Ratio (M-H, Fixed, 99% CI) 1.38 [0.89, 2.14]
3.4 Nervousness 1 318 Risk Ratio (M-H, Fixed, 99% CI) 10.65 [0.78, 146.08]
3.5 Ataxia 1 297 Risk Ratio (M-H, Fixed, 99% CI) 1.24 [0.34, 4.55]
3.6 Nausea 3 769 Risk Ratio (M-H, Fixed, 99% CI) 1.24 [0.69, 2.22]
3.7 Somnolence 3 769 Risk Ratio (M-H, Fixed, 99% CI) 1.18 [0.76, 1.83]
3.8 Infection 1 154 Risk Ratio (M-H, Fixed, 99% CI) 1.0 [0.36, 2.76]
3.9 Headache 1 154 Risk Ratio (M-H, Fixed, 99% CI) 1.15 [0.48, 2.79]
 
 
Analysis 1.1.   Comparison 1 Tiagabine versus placebo control,
Outcome 1 50% or greater reduction in seizure frequency.
Study or subgroup Tiagabine Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.1.1 Intention-to-treat analysis  
Kalviainen 1998 11/77 5/77 20.99% 2.2[0.8,6.03]
Sachdeo 1997 61/211 10/107 55.71% 3.09[1.65,5.79]
Uthman 1998 38/206 4/91 23.3% 4.2[1.54,11.41]
Subtotal (95% CI) 494 275 100% 3.16[1.97,5.07]
Total events: 110 (Tiagabine), 19 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.81, df=2(P=0.67); I2=0%  
Test for overall effect: Z=4.78(P<0.0001)  
   
1.1.2 Worst-case analysis  
Kalviainen 1998 11/77 13/77 20.59% 0.85[0.4,1.77]
Favours Placebo 200.05 50.2 1 Favours tiagabine
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Study or subgroup Tiagabine Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Sachdeo 1997 61/211 20/107 42.05% 1.55[0.99,2.42]
Uthman 1998 38/206 17/91 37.36% 0.99[0.59,1.65]
Subtotal (95% CI) 494 275 100% 1.19[0.88,1.62]
Total events: 110 (Tiagabine), 50 (Placebo)  
Heterogeneity: Tau2=0; Chi2=2.64, df=2(P=0.27); I2=24.15%  
Test for overall effect: Z=1.14(P=0.26)  
   
1.1.3 Best-case analysis  
Kalviainen 1998 32/77 5/77 20.99% 6.4[2.63,15.55]
Sachdeo 1997 98/211 10/107 55.71% 4.97[2.71,9.12]
Uthman 1998 79/206 4/91 23.3% 8.72[3.3,23.1]
Subtotal (95% CI) 494 275 100% 6.14[3.92,9.63]
Total events: 209 (Tiagabine), 19 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.97, df=2(P=0.61); I2=0%  
Test for overall effect: Z=7.92(P<0.0001)  
Favours Placebo 200.05 50.2 1 Favours tiagabine
 
 
Analysis 1.2.   Comparison 1 Tiagabine versus placebo control, Outcome 2 Treatment withdrawal.
Study or subgroup Tiagabine Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Kalviainen 1998 21/77 8/77 20.35% 2.63[1.24,5.56]
Sachdeo 1997 37/211 10/107 33.76% 1.88[0.97,3.63]
Uthman 1998 41/206 13/91 45.88% 1.39[0.79,2.47]
   
Total (95% CI) 494 275 100% 1.81[1.25,2.62]
Total events: 99 (Tiagabine), 31 (Placebo)  
Heterogeneity: Tau2=0; Chi2=1.75, df=2(P=0.42); I2=0%  
Test for overall effect: Z=3.12(P=0)  
Favours Tiagabine 100.1 50.2 20.5 1 Favours Placebo
 
 
Analysis 1.3.   Comparison 1 Tiagabine versus placebo control, Outcome 3 Adverse e6ects.
Study or subgroup Tiagabine Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
1.3.1 Dizziness  
Kalviainen 1998 22/77 8/77 14.12% 2.75[1.03,7.32]
Sachdeo 1997 51/211 21/107 49.17% 1.23[0.68,2.23]
Uthman 1998 64/206 15/91 36.71% 1.88[0.97,3.66]
Subtotal (99% CI) 494 275 100% 1.69[1.13,2.51]
Total events: 137 (Tiagabine), 44 (Placebo)  
Heterogeneity: Tau2=0; Chi2=3.7, df=2(P=0.16); I2=45.94%  
Test for overall effect: Z=3.36(P=0)  
   
1.3.2 Tremor  
Uthman 1998 31/206 3/91 100% 4.56[1,20.94]
Subtotal (99% CI) 206 91 100% 4.56[1,20.94]
Favours Tiagabine 2000.005 100.1 1 Favours Placebo
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Study or subgroup Tiagabine Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
Total events: 31 (Tiagabine), 3 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.57(P=0.01)  
   
1.3.3 Fatigue  
Kalviainen 1998 16/77 12/77 23.35% 1.33[0.55,3.25]
Sachdeo 1997 43/211 14/107 36.15% 1.56[0.75,3.24]
Uthman 1998 42/206 15/91 40.49% 1.24[0.61,2.5]
Subtotal (99% CI) 494 275 100% 1.38[0.89,2.14]
Total events: 101 (Tiagabine), 41 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.35, df=2(P=0.84); I2=0%  
Test for overall effect: Z=1.86(P=0.06)  
   
1.3.4 Nervousness  
Sachdeo 1997 21/211 1/107 100% 10.65[0.78,146.08]
Subtotal (99% CI) 211 107 100% 10.65[0.78,146.08]
Total events: 21 (Tiagabine), 1 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.33(P=0.02)  
   
1.3.5 Ataxia  
Uthman 1998 14/206 5/91 100% 1.24[0.34,4.55]
Subtotal (99% CI) 206 91 100% 1.24[0.34,4.55]
Total events: 14 (Tiagabine), 5 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.42(P=0.67)  
   
1.3.6 Nausea  
Kalviainen 1998 9/77 8/77 24.67% 1.13[0.35,3.66]
Sachdeo 1997 28/211 9/107 36.83% 1.58[0.62,4.03]
Uthman 1998 20/206 9/91 38.5% 0.98[0.37,2.62]
Subtotal (99% CI) 494 275 100% 1.24[0.69,2.22]
Total events: 57 (Tiagabine), 26 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.86, df=2(P=0.65); I2=0%  
Test for overall effect: Z=0.93(P=0.35)  
   
1.3.7 Somnolence  
Kalviainen 1998 11/77 12/77 22.18% 0.92[0.34,2.47]
Sachdeo 1997 41/211 15/107 36.79% 1.39[0.68,2.83]
Uthman 1998 41/206 16/91 41.03% 1.13[0.57,2.25]
Subtotal (99% CI) 494 275 100% 1.18[0.76,1.83]
Total events: 93 (Tiagabine), 43 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.79, df=2(P=0.67); I2=0%  
Test for overall effect: Z=0.95(P=0.34)  
   
1.3.8 Infection  
Kalviainen 1998 11/77 11/77 100% 1[0.36,2.76]
Subtotal (99% CI) 77 77 100% 1[0.36,2.76]
Total events: 11 (Tiagabine), 11 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Favours Tiagabine 2000.005 100.1 1 Favours Placebo
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Study or subgroup Tiagabine Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
1.3.9 Headache  
Kalviainen 1998 15/77 13/77 100% 1.15[0.48,2.79]
Subtotal (99% CI) 77 77 100% 1.15[0.48,2.79]
Total events: 15 (Tiagabine), 13 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.42(P=0.68)  
Favours Tiagabine 2000.005 100.1 1 Favours Placebo
 
 
Comparison 2.   Tiagabine versus topiramate





Statistical method Effect size
1 50% or greater reduction in seizure fre-
quency (ITT)
1 41 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.19, 1.58]
2 Treatment withdrawal (ITT) 1 41 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [0.74, 2.74]
 
 
Analysis 2.1.   Comparison 2 Tiagabine versus topiramate,
Outcome 1 50% or greater reduction in seizure frequency (ITT).
Study or subgroup Tiagabine Topiramate Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Fritz 2005 4/21 7/20 100% 0.54[0.19,1.58]
   
Total (95% CI) 21 20 100% 0.54[0.19,1.58]
Total events: 4 (Tiagabine), 7 (Topiramate)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.12(P=0.26)  
Favours Topiramate 50.2 20.5 1 Favours Tiagabine
 
 
Analysis 2.2.   Comparison 2 Tiagabine versus topiramate, Outcome 2 Treatment withdrawal (ITT).
Study or subgroup Tiagabine Topiramate Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Fritz 2005 12/21 8/20 100% 1.43[0.74,2.74]
   
Total (95% CI) 21 20 100% 1.43[0.74,2.74]
Total events: 12 (Tiagabine), 8 (Topiramate)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.07(P=0.28)  
Favours Tiagabine 20.5 1.50.7 1 Favours Topiramate
 
Tiagabine add-on therapy for drug-resistant focal epilepsy (Review)









Cochrane Database of Systematic Reviews
 
A D D I T I O N A L   T A B L E S
 
Trial Placebo, proportion 16 mg/d 30 to 32 mg/d 56 mg/d
Uthman 1998actual 4.4 8.2 19.3 18.1
Kalviainen 1998actual 6.5   14.3  
Uthman 1998; Kalviainen 1998fitted 6.3 (4.1 to 9.4) 6.3 (4.1 to
9.4)
19.7 (15.2 to 25.0) 19.7 (15.2
to 25.0)
Sachdeo 1997actual 10.2   28.6  
Sachdeo 1997fitted 9.8 (6.4 to 14.9)   28.7 (23.3 to 34.9)  





Rey auditory verbal learning test
Controlled oral word association test
Lafayette grooved pegboard
Benton visual retention test











Verbal learning and memory test (VLMT)
Fritz 2005
Diagnosticum fur cerebralschaden (DSC-R) (visual memory)
Table 2.   Neuropsychological tests used 
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Boston naming test
Word fluency test (LPS)
Token test
Stroop test
Rey auditory verbal learning test
Controlled oral word association test
Modified finger tapping test
Binary choice reaction
Full-scale I.Q. (WAIS)





The WMS visual reproduction subtest
Kalviainen 1996
Auditory and visual reaction times
Stroop test










Table 2.   Neuropsychological tests used  (Continued)
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Test Study Result (P) Treatment favoured
Benton visual retention test, form F Dodrill 1997 0.049 Placebo
Benton visual retention test, form G Dodrill 1997 0.051 Placebo
Symbol digit modalities test Dodrill 1997 0.051 Placebo


















Medicine and medical management




Mood Rating Scale Average score
Befindlichkeits-Skala (BFS) Dysphoria
Beck Depression Inventory Depression
Self-rating Anxiety Scale (SAS) Anxiety
Fritz 2005
QOLIE-31 Health-related quality of life
Sveinbjornsdottir
1994
The Mood Adjective Check List (MACL) Depression
Table 4.   Tests of mood and adjustment 
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Rating Scale Adapted from Brooks and McKin-
lay
Individual's behaviour
Table 4.   Tests of mood and adjustment  (Continued)
 
 
A P P E N D I C E S
Appendix 1. Cochrane Register of Studies (CRS Web) search strategy
1. tiagabin* OR gabitril AND CENTRAL:TARGET
2. MESH DESCRIPTOR Epilepsy EXPLODE ALL AND CENTRAL:TARGET
3. MESH DESCRIPTOR Seizures EXPLODE ALL AND CENTRAL:TARGET
4. (epilep* OR seizure* OR convuls*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
5. #2 OR #3 OR #4 AND CENTRAL:TARGET
6. #1 AND #5
7. #6 AND >04/08/2016:CRSCREATED
Appendix 2. MEDLINE (Ovid) search strategy
This search strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials published in Lefebvre 2011.
1. (Tiagabin* or Gabitril).tw.
2. exp Epilepsy/
3. exp Seizures/
4. (epilep$ or seizure$ or convuls$).tw.
5. 2 or 3 or 4
6. exp *Pre-Eclampsia/ or exp *Eclampsia/
7. 5 not 6
8. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
9. clinical trials as topic.sh.
10. trial.ti.
11. 8 or 9 or 10
12. exp animals/ not humans.sh.
13. 11 not 12
14. 1 and 7 and 13
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15. limit 14 to ed=20160804-20190121
16. 14 not (1$ or 2$).ed.
17. 16 and (2016$ or 2017$ or 2018$ or 2019$).dt.
18. 15 or 17
19. remove duplicates from 18
Appendix 3. ClinicalTrials.gov search strategy
Interventional Studies | Epilepsy | Tiagabine | First posted on or after 08/04/2016
Appendix 4. Cochrane Epilepsy Group Specialized Register search strategy
#1 tiagabin* OR gabitril
#2 INREGISTER AND >11/11/2013:CRSCREATED
#3 #1 AND #2
Appendix 5. CENTRAL via CRSO search strategy
#1 gabitril OR tiagabina OR tiagabine
#2 (epilep* OR seizure* OR convuls*):TI,AB,KY
#3 MESH DESCRIPTOR Epilepsy EXPLODE ALL TREES
#4 MESH DESCRIPTOR Seizures EXPLODE ALL TREES
#5 #2 OR #3 OR #4
#6 #1 AND #5
#7 31/10/2013 TO 31/08/2016:DL
#8 #6 AND #7
#9 ("Conference Abstract"):PT AND INEMBASE
#10 #8 NOT #9
Appendix 6. MEDLINE (Ovid) search strategy
This search strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials published in Lefebvre 2011.
1. (Tiagabin* or Gabitril).tw.
2. exp Epilepsy/
3. exp Seizures/
4. (epilep$ or seizure$ or convuls$).tw.
5. 2 or 3 or 4
6. exp *Pre-Eclampsia/ or exp *Eclampsia/
7. 5 not 6
8. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
9. clinical trials as topic.sh.
10. trial.ti.
11. 8 or 9 or 10
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12. exp animals/ not humans.sh.
13. 11 not 12
14. 1 and 7 and 13
15. limit 14 to ed=20131111-20160804
16. remove duplicates from 15
Earlier versions of this review employed the following search strategy. It was combined with phases 1 and 2 of the earlier Cochrane highly
sensitive search strategy for MEDLINE as set out in Appendix 5b of the Cochrane Handbook for Systematic Reviews of Interventions (version
4.2.4, updated March 2005) (Higgins 2011).
1. tiagabine.tw.
2. exp epilepsy/ OR epilep$.tw.
3. exp seizures/ OR seizure$.tw.
4. convulsion$.tw.
5. 2 OR 3 OR 4
6. 1 AND 5
W H A T ' S   N E W
 
Date Event Description
22 January 2019 New citation required but conclusions
have not changed
Conclusions are unchanged.
22 January 2019 New search has been performed Searches updated 22 January 2019; no new trials identified.
 
H I S T O R Y
Protocol first published: Issue 1, 2000
Review first published: Issue 3, 2002
 
Date Event Description
4 August 2016 New search has been performed Searches updated 04 August 2016; no new trials identified.
4 August 2016 New citation required but conclusions
have not changed
Conclusions remain unchanged.
11 November 2013 New citation required but conclusions
have not changed
Conclusions remain unchanged.
11 November 2013 New search has been performed Searches updated 11 November 2013; no new trials identified.
15 December 2011 New citation required but conclusions
have not changed
Searches updated 15 December 2011; no new trials identified.
11 June 2010 New search has been performed Searches updated 11 June 2010; no new trials identified.
21 August 2008 Amended Converted to new review format.
15 February 2008 New search has been performed Searches updated 15 February 2008; no new trials identified.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
According to the original protocol, we had planned to only include trials using a placebo control group in the review, assuming they met
all other inclusion criteria. We decided to extend this to include any other studies with an active add-on drug, used as a control group
versus tiagabine.
The title of the review has been changed from "Tiagabine add-on for drug-resistant partial epilepsy" to "Tiagabine add-on therapy for drug-
resistant focal epilepsy" in accordance with the latest classification of epilepsies, released by the International League Against Epilepsy
(ILAE) (Scheffer 2017). Any previous mention of "partial epilepsy" within the review text was subsequently changed to "focal epilepsy".
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Drug Resistance;  Anticonvulsants  [adverse eCects]  [*therapeutic use];   Cognition  [drug eCects];   Epilepsies, Partial  [*drug therapy];
  Nipecotic Acids  [adverse eCects]  [*therapeutic use];  Randomized Controlled Trials as Topic;  Tiagabine
MeSH check words
Humans
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